CStone to present bispecific antibody for inflammatory diseases at ACAAI

CStone Pharmaceuticals announced that its autoimmune and inflammation pipeline candidate, CS2015 (OX40L/TSLP bispecific antibody), has been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting. The presentation will be an in-person ePoster - Meet the Author session, scheduled for Friday, November 7, 2025, at 3:05 PM ET in Orlando, USA.

CS2015 is described as a potential first-in-class/best-in-class bispecific antibody designed to target both OX40L and TSLP, thereby blocking two key ligands in Th2-mediated inflammatory signaling pathways. This novel mechanism is intended to address Type 2 inflammatory diseases such as atopic dermatitis, asthma, and chronic obstructive pulmonary disease. The presentation, titled "CS2015 a TSLP/OX40L Bispecific Antibody as a Potential Novel Therapeutic Agent for Type 2 Inflammation Diseases," will have an abstract ID of 8079 and ePoster ID: R377.

CStone Pharmaceuticals, established in late 2015, focuses on developing therapies for oncology, autoimmune/inflammation, and other key disease areas. The company has launched four innovative drugs and secured approvals for 16 new drug applications across nine indications. The pipeline includes 16 candidates, featuring antibody-drug conjugates, multispecific antibodies, immunotherapies, and precision medicines.